The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide.

Abstract

Fifty-four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by intramuscular injection and continuous oral cyclophosphamide, the dose of the latter being varied to maintain the patient's white cell count at about 1.5 x 10(9)/l. A combined partial and complete remission rate of 76 per cent was obtained. The length of survival depended upon the type of remission and the type of remission was markedly affected by the amount of tumour removed at initial laparotomy.

• Authors: D Guthrie
• Journal: British journal of obstetrics and gynaecology (Br J Obstet Gynaecol) Vol. 86 Issue 7 Pg. 497-500 (Jul 1979) ISSN: 0306-5456 [Print] England
• PMID: 476014 (Publication Type: Journal Article)

Chemical References

• Cyclophosphamide
• Gestonorone Caproate

Topics

• Cyclophosphamide (therapeutic use)
• Cystadenocarcinoma (drug therapy, mortality)
• Drug Therapy, Combination
• Female
• Gestonorone Caproate (therapeutic use)
• Humans
• Leukocyte Count
• Neoplasm Staging
• Ovarian Neoplasms (drug therapy, mortality)